Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 10:52 am Purchase | 2024-09-30 | 13G | Akero Therapeutics, Inc. AKRO | WELLINGTON MANAGEMENT GROUP LLP | 7,896,632 11.370% | 867,008 (+12.33%) | Filing History |
| 2024-10-17 11:13 am Sale | 2024-09-30 | 13G | Akero Therapeutics, Inc. AKRO | STATE STREET CORP STT | 2,502,946 3.600% | -2,619,949 (-51.14%) | Filing History |
| 2024-09-09 09:09 am Purchase | 2024-08-30 | 13G | Akero Therapeutics, Inc. AKRO | WELLINGTON MANAGEMENT GROUP LLP | 7,029,624 10.120% | 4,147,635 (+143.92%) | Filing History |
| 2024-06-10 4:17 pm Purchase | 2024-05-31 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 6,950,418 10.100% | 2,644,017 (+61.40%) | Filing History |
| 2024-03-15 10:08 am Purchase | 2024-03-06 | 13G | Akero Therapeutics, Inc. AKRO | GENERAL ATLANTIC, L.P. | 5,233,989 7.700% | 5,233,989 (New Position) | Filing History |
| 2024-02-14 4:26 pm Sale | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Redmile Group, LLC | 1,109,476 2.000% | -1,523,436 (-57.86%) | Filing History |
| 2024-02-14 4:21 pm Unchanged | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Baker Bros. Advisors LP | 2,368,378 4.300% | 0 (Unchanged) | Filing History |
| 2024-02-14 2:19 pm Unchanged | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | PFIZER INC PFE | 2,525,252 4.530% | 0 (Unchanged) | Filing History |
| 2024-02-14 10:03 am Purchase | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | T. Rowe Price Associates, Inc. | 3,681,209 6.600% | 1,280,172 (+53.32%) | Filing History |
| 2024-02-14 07:06 am Purchase | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | RTW Investments, LP | 3,592,759 6.400% | 3,592,759 (New Position) | Filing History |
| 2024-02-13 9:40 pm Sale | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Avidity Partners Management LP | 235,000 0.400% | -3,590,000 (-93.86%) | Filing History |
| 2024-02-13 6:30 pm Purchase | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Alkeon Capital Management LLC | 3,764,220 6.800% | 520,305 (+16.04%) | Filing History |
| 2024-02-13 4:58 pm Purchase | 2023-12-29 | 13G | Akero Therapeutics, Inc. AKRO | The Vanguard Group | 3,085,048 5.540% | 3,085,048 (New Position) | Filing History |
| 2024-02-13 11:31 am Purchase | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 4,306,401 7.700% | 966,227 (+28.93%) | Filing History |
| 2024-02-08 10:05 am Purchase | 2023-12-29 | 13G | Akero Therapeutics, Inc. AKRO | WELLINGTON MANAGEMENT GROUP LLP | 2,881,989 5.170% | 2,005,890 (+228.96%) | Filing History |
| 2024-02-07 07:23 am Sale | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | ADAGE CAPITAL PARTNERS GP L.L.C. | 275,000 0.490% | -2,527,627 (-90.19%) | Filing History |
| 2024-01-26 11:49 am Purchase | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | BlackRock Inc. BLK | 4,180,507 7.500% | 1,421,978 (+51.55%) | Filing History |
| 2024-01-25 09:36 am Purchase | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | STATE STREET CORP STT | 5,122,895 9.200% | 2,621,926 (+104.84%) | Filing History |
| 2023-09-12 4:30 pm Sale | 2023-09-08 | 13G | Akero Therapeutics, Inc. AKRO | Skorpios Trust | 0 0.000% | -3,271,829 (Position Closed) | Filing History |
| 2023-04-10 4:59 pm Purchase | 2023-03-30 | 13G | Akero Therapeutics, Inc. AKRO | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,802,627 5.970% | 2,802,627 (New Position) | Filing History |